Massachusetts Financial Services Trims Stake in Johnson & Johnson

Institutional investor reduces holdings in pharmaceutical giant amid broader market shifts

Apr. 14, 2026 at 9:55am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white macro photograph of the inner workings of a complex financial system, conveying a sense of the scale, precision, and security underlying a large corporation's financial infrastructure.An extreme close-up of the intricate machinery and components that power the financial operations of a major pharmaceutical conglomerate like Johnson & Johnson.New Brunswick Today

Massachusetts Financial Services Co. MA, a major institutional investor, has trimmed its stake in Johnson & Johnson (NYSE: JNJ) by 6.7% during the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns approximately 16.4 million shares of the pharmaceutical company, valued at $3.39 billion.

Why it matters

This reduction in holdings by a prominent institutional investor highlights the shifting dynamics in the healthcare and pharmaceutical sectors, as investors weigh factors like growth prospects, valuation, and market conditions when allocating capital. Johnson & Johnson's performance and outlook will continue to be closely watched by the investment community.

The details

According to the 13F filing, Massachusetts Financial Services Co. MA sold 1,172,786 shares of Johnson & Johnson during the fourth quarter. The firm now owns around 0.68% of the company's outstanding shares. Johnson & Johnson remains the 7th largest holding in Massachusetts Financial Services' investment portfolio.

  • The stake reduction occurred during the fourth quarter of 2025.
  • Massachusetts Financial Services Co. MA filed the 13F report disclosing the changes on April 14, 2026.

The players

Massachusetts Financial Services Co. MA

A major institutional investment management firm that oversees a diversified portfolio of equity and fixed-income assets.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor the performance and outlook of large-cap healthcare names like Johnson & Johnson as the market environment evolves.”

— Analyst

What’s next

Investors will be closely watching Johnson & Johnson's upcoming Q1 earnings report and guidance for any signs of changing market dynamics or shifts in the company's business performance.

The takeaway

This reduction in holdings by a prominent institutional investor underscores the need for Johnson & Johnson to maintain a strong competitive position and deliver consistent financial results in order to retain the confidence of the investment community.